stride trial semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled 🔴The STRIDE trial! 👟⤵️ 🔹The

Evolving regulatory landscape: The FDAs enforcement posture on compounded GLP-1 products has intensified significantly since 2025

GLP-1 receptor agonists such as semaglutide and tirzepatide amplify the bodys GLP-1 response, restoring more normal signaling and offering substantial benefits for blood sugar regulation and sustainable weight loss

People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not take it

Weight loss greater than 1015% of body weight over a short period increases the likelihood of this response

Wrapping It Up Semaglutide and other GLP-1 inhibitors can be powerful tools in your health journey if used and dosed correctly and in combination with great lifestyle habits, helping you manage weight, blood pressure, and Type 2 Diabetes

Some patients benefit from a slower titration schedule, remaining at lower doses for extended periods